BusinessNews Pulse
LigaChem Doses First Patient in Global Trial of Cancer-Targeting ADC
LigaChem Biosciences has begun global clinical development of its proprietary Claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC) candidat…
Read the full pulseContinue in Briflio to read, react, comment, and share.
Sources